Stoke Therapeutics, Inc. $STOK Shares Sold by UBS Group AG

UBS Group AG lessened its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 44.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,713 shares of the company’s stock after selling 136,324 shares during the period. UBS Group AG’s holdings in Stoke Therapeutics were worth $5,387,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Principal Financial Group Inc. bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $1,062,000. Penserra Capital Management LLC bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $3,539,000. Vanguard Group Inc. raised its holdings in shares of Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares during the last quarter. Baillie Gifford & Co. bought a new stake in shares of Stoke Therapeutics during the fourth quarter valued at approximately $7,837,000. Finally, Checkpoint Capital L.P. bought a new stake in shares of Stoke Therapeutics during the third quarter valued at approximately $4,983,000.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $29.67 on Friday. Stoke Therapeutics, Inc. has a 12 month low of $9.09 and a 12 month high of $40.22. The firm has a market capitalization of $1.85 billion, a PE ratio of -10.56 and a beta of 1.20. The company’s 50 day simple moving average is $33.36 and its 200 day simple moving average is $31.94.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The business had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. Sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wall Street Zen cut Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Wedbush lifted their price target on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Tuesday, March 17th. Canaccord Genuity Group lifted their price target on Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Finally, Needham & Company LLC raised their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.83.

Insider Buying and Selling at Stoke Therapeutics

In related news, Director Adrian R. Krainer sold 33,243 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total transaction of $1,321,076.82. Following the transaction, the director owned 283,302 shares in the company, valued at $11,258,421.48. This trade represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barry Ticho sold 6,686 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24. Following the transaction, the insider owned 40,798 shares in the company, valued at $1,278,609.32. This represents a 14.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 69,699 shares of company stock valued at $2,526,714. 9.50% of the stock is currently owned by company insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.